Abelacimab in Cancer-Associated Thrombosis: The Right Drug at the Right Time for the Right Purpose. A Comprehensive Review

Abelacimab in Cancer-Associated Thrombosis: The Right Drug at the Right Time for the Right Purpose. A Comprehensive Review

Cancer-associated thrombosis (CAT) is a devastating complication of cancer that can significantly impact a patient’s health and life. The incidence of CAT is approximately 20%, and 1 in 5 cancer patients will develop CAT annually. Indeed, CAT can promote pulmonary embolism and deep vein thrombosis,...

Full description

Bibliographic Details
Main Authors: Agnese Maria Fioretti, Tiziana Leopizzi, Daniele La Forgia, Raffaele De Luca, Donato Oreste, Riccardo Inchingolo, Pietro Scicchitano, Stefano Oliva
Format: Article
Language:English
Published: IMR Press 2023-10-01
Series:Reviews in Cardiovascular Medicine
Subjects:
cancer-associated thrombosis
factor xi inhibitors
abelacimab
bleeding risk
Online Access:https://www.imrpress.com/journal/RCM/24/10/10.31083/j.rcm2410295

Similar Items

Similar Items